AnaptysBio's new drug, rosnilimab, has shown promise in a phase 2 trial for treating rheumatoid arthritis (RA), as reported by Waldron (2025). The trial met its primary objectives, indicating that the drug can effectively reduce the symptoms of RA. Rosnilimab, which is a PD-1 agonist, works by targeting a specific pathway in the immune system that can contribute to the inflammation and joint damage characteristic of RA. The success of this trial is particularly significant given the setbacks AnaptysBio faced the previous year.
The positive results from this study suggest that rosnilimab could be a viable new treatment option for RA patients. The specifics of the trial, such as the number of participants and the statistical significance of the results, were not detailed in the abstract but the achievement of the trial's goals suggests that the drug could move forward in the development process.
